NEW YORK, July 7, 2016 /PRNewswire/ --
On Wednesday, July 06, 2016, the
NASDAQ Composite ended the trading session at 4,859.16, up 0.75%;
the Dow Jones Industrial Average edged 0.44% higher, to finish at
17,918.62; and the S&P 500 closed at 2,099.73, up 0.54%. The
gains were broad based as eight out of nine sectors ended the
session in positive. Stock-Callers.com has initiated coverage on
the following equities: Exelixis Inc. (NASDAQ: EXEL), Novavax Inc.
(NASDAQ: NVAX), Celgene Corporation (NASDAQ: CELG), and Ariad
Pharmaceuticals Inc. (NASDAQ: ARIA). Learn more about these stocks
by accessing their free notes at:
http://stock-callers.com/registration
South San Francisco, California
headquartered biopharmaceutical Company, Exelixis Inc.'s stock
advanced 1.12% to close the day at $8.14 with a total volume of 5.87 million shares
traded. The Company's shares have surged 11.05% in the last one
month and 82.51% in the past three months. Furthermore, the
Company's stock has rallied 131.91% in the previous one year. The
stock is trading 28.90% and 54.21% above its 50-day and 200-day
moving averages, respectively. Additionally, Exelixis' stock has a
Relative Strength Index (RSI) of 73.36. Sign up and read the free
notes on EXEL at:
http://stock-callers.com/registration/?symbol=EXEL
Gaithersburg, Maryland
headquartered clinical-stage vaccine Company, Novavax Inc.'s stock
finished Wednesday's session 3.18% higher at $7.46 with a total volume of 3.95 million shares
traded. Over the last one month and the previous three months, the
Company's shares have gained 15.30% and 31.34%, respectively. The
stock is trading above its 50-day and 200-day moving averages by
26.89% and 16.53%, respectively. Novavax's stock has an RSI of
66.68. The complimentary notes on NVAX can be downloaded in PDF
format at:
http://stock-callers.com/registration/?symbol=NVAX
On Wednesday, shares in Celgene Corp. which discovers, develops,
and commercializes therapies to treat cancer and inflammatory
diseases worldwide, ended the session 4.34% higher at $104.60 with a total volume of 7.35 million
shares traded. Shares of the Company traded at a PE ratio of 50.60.
The stock is trading 2.10% above its 50-day moving average.
Moreover, shares of Celgene have an RSI of 59.45. Register for free
on Stock-Callers.com and access the latest notes on CELG at:
http://stock-callers.com/registration/?symbol=CELG
On Wednesday, shares in Cambridge,
Massachusetts headquartered oncology Company, Ariad
Pharmaceuticals Inc., ended the day 1.52% higher at $7.37 with a total volume of 2.12 million shares
traded. The Company's shares have gained 12.52% in the previous
three months. The stock is trading above its 200-day moving average
by 11.79%. Furthermore, shares of Ariad Pharmaceuticals have an RSI
of 46.41. Get free access to your notes on ARIA at:
http://stock-callers.com/registration/?symbol=ARIA
Stock Callers:
Stock Callers (SC) produces regular sponsored and non-sponsored
reports, articles, stock market blogs, and popular investment
newsletters covering equities listed on NYSE and NASDAQ and
micro-cap stocks. SC has two distinct and independent departments.
One department produces non-sponsored analyst certified content
generally in the form of press releases, articles and reports
covering equities listed on NYSE and NASDAQ and the other produces
sponsored content (in most cases not reviewed by a registered
analyst), which typically consists of compensated investment
newsletters, articles and reports covering listed stocks and
micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
SC has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer") represented by a
credentialed financial analyst [for further information on analyst
credentials, please email info@stock-callers.com . Rohit Tuli, a CFA® charterholder (the
"Sponsor"), provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as
necessary, based on publicly available information which is
believed to be reliable. Content is researched, written and
reviewed on a reasonable-effort basis. The Reviewer has not
performed any independent investigations or forensic audits to
validate the information herein. The Reviewer has only
independently reviewed the information provided by the Author
according to the procedures outlined by SC. SC is not entitled to
veto or interfere in the application of such procedures by the
third-party research service company to the articles, documents or
reports, as the case may be. Unless otherwise noted, any content
outside of this document has no association with the Author or the
Reviewer in any way.
NO WARRANTY
SC, the Author, and the Reviewer are not responsible for any
error which may be occasioned at the time of printing of this
document or any error, mistake or shortcoming. No liability is
accepted whatsoever for any direct, indirect or consequential loss
arising from the use of this document. SC, the Author, and the
Reviewer expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from
any reliance placed on the information in this document.
Additionally, SC, the Author, and the Reviewer do not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the
information. The included information is subject to change without
notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither SC nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit
http://stock-callers.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly.
If you're a company we are
covering and wish to no longer feature on our coverage list contact
us via email and/or phone between 09:30 EDT
to 16:00 EDT from Monday to Friday at:
Email: info@stock-callers.com
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street,
Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Chelmsford Park SA